2026 Acute Pulmonary Embolism Guideline

Professor Mark A. Creager provides an in-depth overview of the newly released 2026 Acute Pulmonary Embolism Guideline, highlighting key updates in clinical management and patient outcomes at the ACC 2026 Annual Congress.

Highlights of ACC.26

Professor Christopher Kramer shares the most significant breakthroughs, late-breaking clinical trials, and key takeaways from the ACC 2026 Annual Congress, summarizing the future of cardiovascular care.

Efficacy and Safety of Enlicitide Decanoate: Results from the Phase 3 CORALreef AddOn Trial

Professor Alberico L. Catapano presents findings from the Phase 3 CORALreef AddOn trial, evaluating the oral PCSK9 inhibitor enlicitide decanoate versus bempedoic acid and ezetimibe in statin-treated patients with hypercholesterolemia.

Interventional Cardiology Highlights of ACC.26

Professor Roxana Mehran provides an expert review of the most impactful interventional cardiology developments from the ACC 2026 Annual Congress, focusing on new stent technologies, structural heart interventions, and complex PCI outcomes.

Navigating AHA Scientific Statements: Advancing Evidence-Based Cardiovascular Care

Professor Bradley S. Marino shares his insights on the advancing evidence-based cardiovascular care at AHA Scientific Sessions 2025.

Aldosterone and Mineralocorticoid Receptors: New Paradigms and Novel Therapies

Professor John M. Flack shares his insights on the new paradigms and novel therapies in aldosterone and mineralocorticoid receptors at AHA Scientific Sessions 2025.

TUXEDO-2: Ticagrelor vs. Prasugrel in Patients With Diabetes and Multivessel Disease After PCI

Professor Sripal Bangalore discusses the findings from the TUXEDO-2 trial presented at at AHA Scientific Sessions 2025.

DASH-Patterned Groceries Reduce Blood Pressure

Professor Stephen P. Juraschek discusses the results from the GoFresh randomized clinical trial presented at at AHA Scientific Sessions 2025.

Blood Pressure and Symptomatic Hypotension with Dapagliflozin vs. Placebo in Patients Hospitalized with Heart Failure

Professor Siddharth M. Patel shares his insights on the results from the DAPA ACT HF-TIMI 68 trial at AHA Scientific Sessions 2025.

Effectiveness of High-Dose vs. Standard-Dose Inactivated Influenza Vaccine in Individuals with and without Atherosclerotic Cardiovascular Disease: A Pooled FLUNITY-HD Trial Analysis

Professor Manan Pareek shares his insights on the results from the FLUNITY-HD trial analysis at AHA Scientific Sessions 2025.

Remote BP Monitoring and Drug Titration – Does it work? How do we do it?

Professor Beverly B. Green shares her insights on remote BP monitoring and drug titrationat after the AHA Scientific Sessions 2025.

Highlights of AHA / ACC Blood Pressure Management Guideline

Professor Daniel Jones shares his insights on the AHA / ACC  Blood Pressure Management Guideline at AHA Scientific Sessions 2025.

Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation

Professor Amrish Deshmukh shares his insights on metformin as an adjunctive therapy to catheter ablation of atrial fibrillation at AHA Scientific Sessions 2025.

Resistance Exercise Therapy After COVID-19 Infection: a Randomized, Controlled Trial

Professor Stuart Gray shares his insights on the resistance exercise therapy after COVID-19 infection at AHA Scientific Sessions 2025.

Impact of Cardiovascular-Focused Messaging to Improve Influenza Vaccination on Cardiovascular-Kidney-Metabolic Care Patterns and Clinical Outcomes: Insights from the KP VACCINATE Megatrial

Professor Ankeet Bhatt shares his insights from the KP VACCINATE Megatrial presented at at AHA Scientific Sessions 2025.

Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure

Professor Stephen Nicholls shares his insights on the pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial at AHA Scientific Sessions 2025.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention